Translational Development Acquisition (TDACW) Shares Outstanding (2023 - 2026)

Translational Development Acquisition (TDACW) has reported Shares Outstanding (Entity) for 4 consecutive years, with $28.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 7.75% year-over-year to $28.6 million; the trailing twelve-month figure through Jun 2026 stood at $28.6 million (up 7.75% YoY), and the FY2025 full-year result was $26.6 million, up 2.29% from the prior year.
• Shares Outstanding (Entity) improved to $28.6 million in Q2 2026 per TDACW's latest filing, from $26.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $28.6 million in Q2 2026 and bottomed at $8.1 million in Q4 2023.
• Historically, Shares Outstanding (Entity) has averaged $24.6 million across 4 years, with a median of $26.6 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) soared 220.61% in 2024, then changed 0.0% in 2026.
• Over 4 years, Shares Outstanding (Entity) stood at $8.1 million in 2023, then jumped by 220.61% to $26.0 million in 2024, then rose by 2.29% to $26.6 million in 2025, then grew by 7.75% to $28.6 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $28.6 million, $26.6 million, and $26.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.